Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 26, 2022

Intensity-Modulated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol 2022 Sep 13;[EPub Ahead of Print], AC Tree, P Ostler, H van der Voet, W Chu, A Loblaw, D Ford, S Tolan, S Jain, A Martin, J Staffurth, J Armstrong, P Camilleri, K Kancherla, J Frew, A Chan, IS Dayes, A Duffton, DH Brand, D Henderson, K Morrison, S Brown, J Pugh, S Burnett, M Mahmud, V Hinder, O Naismith, E Hall, N van As

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading